Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jonathan Hoggatt
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Magenta Therapeutics
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Hoggatt is a co-founder of, and consultant for, Magenta Therapeutics, a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. The company is creating a portfolio of therapeutics that target all aspects of the bone marrow transplant process, including patient preparation, stem cell harvesting, stem cell expansion and post-transplant complications. The research seeks to identify the mechanism(s) that improve hematopoietic stem cell transplantation and develop non-toxic conditioning methods to allow for successful transplantation. The research and the company are both focused on improving the bone marrow transplant process and, if the research is successful, the company may have an interest in the resulting IP. The Partners Committee on Outside Activities reviewed the financial interest in connection with the research and determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research. The committee determined that the conflict could be managed with the implementation of an FCOI management plan.
Enhancing Bone Marrow Transplantation With Highly Engraftable Hematopoietic Stem Cells
PROJECT NARRATIVE Bone marrow transplant is a potential cure for diseases such as blood cancers or blood disorders, but also for autoimmune diseases, metabolic disorders, and others. Treatment strategies for these diseases require high quality blood-forming stem cells and less toxic methods of preparing the patient that do not require chemotherapy or radiation. This proposal will seek to define what makes stem cells better at transplanting in a patient and will develop non-toxic conditioning methods to allow for successful transplantation.
Filed on January 15, 2019.
Tell us what you know about Jonathan Hoggatt's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jonathan Hoggatt filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jonathan Hoggatt | Massachusetts General Hospital | Conflict of Interest | Magenta Therapeutics | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.